All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Clinical trial club: Navtemadlin vs best available therapy in relapsed or refractory myelofibrosis

Aug 15, 2022
Share:
Learning objective: After reading this article, learners will be able to describe MDM2 inhibition in MF, key phase II data for navtemadlin, and explain the role of navtemadlin in the therapeutic landscape.

On July 19, 2022, Scientific Education Support held its first clinical trial club, entitled “BOREAS trial: Navtemadlin (KRT-232) vs best available therapy in relapsed/refractory MF.” This live webinar was part of the MPN Hub Clinical Trial Club webinar series, entitled “Novel agents for the treatment of advanced myelofibrosis.”

The live webinar aimed to discuss the phase II and phase III navtemadlin clinical trials (NCT03662126), investigating navtemadlin, a murine double minute 2 (MDM2) inhibitor, in patients with myelofibrosis (MF) who relapse on, or are refractory to, Janus kinase (JAK) inhibitors. The event was chaired by Laura Michaelis, Medical College of Wisconsin, Milwaukee, US, and presented by the trial investigator Haifa Kathrin Al-Ali, University Hospital Halle (Saale), Halle, DE.

During the webinar, Haifa Kathrin Al-Ali talked about MDM2 inhibition in MF, and presented safety and efficacy data from the phase II trial. Subsequently, the two speakers discussed what these findings, and the ongoing randomized controlled phase III BOREAS trial, mean for clinical practice, which was followed by a live Q&A session.

Clinical trial club: Navtemadlin vs best available therapy in relapsed or refractory myelofibrosis

What do the navtemadlin trials mean for clinical practice?

Overview of the navtemadlin trials (NCT03662126)

MDM2 inhibition in MF

Key phase II efficacy and safety findings